0
To amend the Federal Food, Drug, and Cosmetic Act to include a safe harbor for communication of information with respect to a vaccine authorized for emergency use under such Act that is provided or distributed to a health care provider, and for other purposes.
12/30/2022, 5:32 PM
Summary of Bill HR 3705
The main goal of this bill is to create a safe harbor for communication related to emergency use vaccines, allowing health care providers to share vital information with their patients without facing potential legal challenges. This is especially important during times of public health emergencies, such as the current COVID-19 pandemic, where clear and accurate communication about vaccines is crucial.
By providing this safe harbor, the bill aims to promote transparency and trust in the vaccine distribution process, ultimately leading to increased vaccination rates and improved public health outcomes. Additionally, the bill includes provisions for other purposes related to vaccine communication, further emphasizing the importance of clear and accurate information sharing in the healthcare field. Overall, Bill 117 hr 3705 seeks to enhance communication surrounding emergency use vaccines and ensure that health care providers have the necessary protections to effectively educate and inform their patients about the importance of vaccination.
Congressional Summary of HR 3705
This bill prohibits using certain communications to establish that a vaccine authorized for emergency use violates specified laws relating to drug safety, such as laws concerning drug misbranding and the authorization of new drugs.
Specifically, the bill applies to certain communications about the use of such a vaccine that has been provided to certain health care entities. Such a communication must be (1) neither false nor misleading when measured objectively against the available information at the time; (2) accompanied by certain disclaimers, if required, including a statement identifying any differences between the communicated information and the vaccine's authorized labeling; and (3) based on competent and reliable scientific evidence.
